Cargando…

Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells

BACKGROUND: Epithelial ovarian cancer (EOC) cells are prone to metastasise throughout the peritoneal cavity. The epithelial-to-mesenchymal transition (EMT) is a necessary step towards metastatic tumour progression. CA125/MUC16 mucin is a high-molecular-weight glycoprotein overexpressed in the majori...

Descripción completa

Detalles Bibliográficos
Autores principales:	Comamala, M, Pinard, M, Thériault, C, Matte, I, Albert, A, Boivin, M, Beaudin, J, Piché, A, Rancourt, C
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065274/ https://www.ncbi.nlm.nih.gov/pubmed/21326240 http://dx.doi.org/10.1038/bjc.2011.34

Ejemplares similares

Thyrostimulin-TSHR signaling promotes the proliferation of NIH:OVCAR-3 ovarian cancer cells via trans-regulation of the EGFR pathway
por: Huang, Wei-Lin, et al.
Publicado: (2016)

MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression
por: Matte, Isabelle, et al.
Publicado: (2014)

Design and mechanism of action of a novel cytotoxic 1,2,3-triazene-containing heterocycle, 3,5-dimethyl-pyrido-1,2,3,5-tetrazepin-4-one (PYRZ), in the human epithelial ovarian cancer cell line NIH:OVCAR-3 in vitro.
por: Jean-Claude, B. J., et al.
Publicado: (1997)

MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer
por: Matull, W R, et al.
Publicado: (2008)

Overexpression and altered glycosylation of MUC1 in malignant mesothelioma
por: Creaney, J, et al.
Publicado: (2008)

Downregulation of EGFR in hypoxic, diffusion-limited areas of squamous cell carcinomas of the head and neck
por: Mayer, Arnulf, et al.
Publicado: (2016)

Promoter CpG methylation in cancer cells contributes to the regulation of MUC4
por: Yamada, N, et al.
Publicado: (2009)

Apical MUC1 expression revealed on the foveolar epithelium in H. pylori gastritis
por: Rashid, M, et al.
Publicado: (2013)

MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells
por: Ponnusamy, M P, et al.
Publicado: (2008)

Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients
por: Lane, Denis, et al.
Publicado: (2011)

The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer
por: Lane, Denis, et al.
Publicado: (2010)

Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis
por: Lane, Denis, et al.
Publicado: (2012)

Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin
por: Bafna, S, et al.
Publicado: (2009)

Analogues of Y27632 increase gap junction communication and suppress the formation of transformed NIH3T3 colonies
por: Hampson, L, et al.
Publicado: (2009)

Validation of histomolecular classification utilizing histological subtype, MUC1, and CDX2 for prognostication of resected ampullary adenocarcinoma
por: Schueneman, A, et al.
Publicado: (2015)

Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting
por: Bradbury, Alice, et al.
Publicado: (2020)

EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer
por: Ålgars, A, et al.
Publicado: (2011)

Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status
por: Rego, R L, et al.
Publicado: (2010)

Specific induction of pp125 focal adhesion kinase in human breast cancer
por: Watermann, D O, et al.
Publicado: (2005)

NF-κB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation
por: Van Laere, S J, et al.
Publicado: (2007)

Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway
por: Matte, Isabelle, et al.
Publicado: (2019)

Role of malignant ascites on human mesothelial cells and their gene expression profiles
por: Matte, Isabelle, et al.
Publicado: (2014)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

Downregulation of miR-302c and miR-520c by 1,25(OH)2D3 treatment enhances the susceptibility of tumour cells to natural killer cell-mediated cytotoxicity
por: Min, D, et al.
Publicado: (2013)

Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer
por: Burford, B, et al.
Publicado: (2013)

MicroRNA-125b regulates proliferation and radioresistance of oral squamous cell carcinoma
por: Shiiba, M, et al.
Publicado: (2013)

The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells
por: Goncharenko-Khaider, N, et al.
Publicado: (2010)

Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis
por: Goncharenko-Khaider, Nadzeya, et al.
Publicado: (2012)

EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target
por: Iida, K, et al.
Publicado: (2011)

Targeting EGFR and PI3K pathways in ovarian cancer
por: Glaysher, S, et al.
Publicado: (2013)

Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options
por: Scartozzi, M, et al.
Publicado: (2007)

Loss of Coxsackie and adenovirus receptor downregulates α-catenin expression
por: Stecker, K, et al.
Publicado: (2009)

Deregulation of MUC4 in gastric adenocarcinoma: potential pathobiological implication in poorly differentiated non-signet ring cell type gastric cancer
por: Senapati, S, et al.
Publicado: (2008)

Can (18)F-FDG PET/CT predict EGFR status in patients with non-small cell lung cancer? A systematic review and meta-analysis
por: Du, Bulin, et al.
Publicado: (2021)

Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10
por: Modjtahedi, H, et al.
Publicado: (2012)

Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients
por: Ruiz, M I Galleges, et al.
Publicado: (2009)

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
por: Yoshikawa, D, et al.
Publicado: (2008)

Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands
por: Lujan, B, et al.
Publicado: (2010)

Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis
por: Lane, Denis, et al.
Publicado: (2013)

Lacking hypoxia-mediated downregulation of E-cadherin in cancers of the uterine cervix
por: Mayer, A, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_r8d94li5i0lv0qgn7ap5p2nqoq